- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06807437
Lanreotid gegen Placebo vor der Operation, um eine chirurgische Komplikation zu verhindern, die als Pankreasfistel bezeichnet wird
Eine randomisierte Phase -III -geblinde Studie mit Lanreotid zur Verhinderung der postoperativen Pankreasfistel
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
I. To compare the incidence of postoperative pancreatic fistula (POPF) occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo prior to undergoing distal pancreatectomy for biopsy-proven or suspected neoplasm.
SECONDARY OBJECTIVES:
I. To compare the incidence of International Study Group of Pancreatic Surgery (ISGPS)-defined biochemical leak occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo in the subset of participants with a drain placed.
II. To compare the number of postoperative days in the hospital within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo.
III. To compare change from baseline in cancer-specific quality of life at 14 and 60 days after surgery, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30-(C30), in participants randomized to receive preoperative lanreotide versus placebo.
ADDITIONAL OBJECTIVES:
I. To compare change from baseline in pancreatic cancer-specific quality of life and overall health-related quality of life at 14 and 60 days after surgery, as measured by the EORTC QLQ- Pancreatic Cancer 26 (PAN26) and European Quality of Life Five Dimension Five Level (EQ-5D-5L), in participants randomized to receive preoperative lanreotide versus placebo.
II. To compare the proportions of participants with common postoperative sequelae associated with POPF, including ISGPS delayed gastric emptying and ISGPS post pancreatectomy hemorrhage (grades B/C) occurring within 60 days after surgery, in participants randomized to receive preoperative lanreotide versus placebo.
III. To compare time from surgery to initiation of adjuvant chemotherapy among participants with pancreatic ductal adenocarcinoma and planned adjuvant chemotherapy randomized to receive preoperative lanreotide versus placebo.
BANKING OBJECTIVE:
I. To bank blood, pancreas fluid, and tissue specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive lanreotide subcutaneously (SC) over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.
ARM II: Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.
After completion of study treatment, patients are followed up at 4, 8 and 12 months after surgery.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Dana Sparks
- Telefonnummer: 210-614-8808
- E-Mail: dsparks@swog.org
Studieren Sie die Kontaktsicherung
- Name: Andrea Garcia
- Telefonnummer: 210-614-8808
- E-Mail: agarcia@swog.org
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- Suspendiert
- University of Alabama at Birmingham Cancer Center
-
Daphne, Alabama, Vereinigte Staaten, 36526
- Suspendiert
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
-
Fairhope, Alabama, Vereinigte Staaten, 36532
- Suspendiert
- Thomas Hospital
-
Mobile, Alabama, Vereinigte Staaten, 36607
- Suspendiert
- Mobile Infirmary Medical Center
-
Saraland, Alabama, Vereinigte Staaten, 36571
- Suspendiert
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
-
-
Arizona
-
Gilbert, Arizona, Vereinigte Staaten, 85234
- Suspendiert
- Banner MD Anderson Cancer Center
-
-
California
-
Duarte, California, Vereinigte Staaten, 91010
- Suspendiert
- City of Hope Comprehensive Cancer Center
-
La Jolla, California, Vereinigte Staaten, 92093
- Rekrutierung
- UC San Diego Moores Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 858-822-5354
- E-Mail: cancercto@ucsd.edu
-
Hauptermittler:
- Andrew M. Lowy
-
Loma Linda, California, Vereinigte Staaten, 92357
- Suspendiert
- Veterans Affairs Loma Linda Healthcare System
-
Los Angeles, California, Vereinigte Staaten, 90033
- Suspendiert
- USC / Norris Comprehensive Cancer Center
-
San Diego, California, Vereinigte Staaten, 92103
- Suspendiert
- UC San Diego Medical Center - Hillcrest
-
-
Delaware
-
Newark, Delaware, Vereinigte Staaten, 19718
- Suspendiert
- Christiana Care Health System-Christiana Hospital
-
Newark, Delaware, Vereinigte Staaten, 19713
- Suspendiert
- Helen F Graham Cancer Center
-
Newark, Delaware, Vereinigte Staaten, 19713
- Suspendiert
- Medical Oncology Hematology Consultants PA
-
Wilmington, Delaware, Vereinigte Staaten, 19801
- Suspendiert
- Christiana Care Health System-Wilmington Hospital
-
-
Florida
-
Ruskin, Florida, Vereinigte Staaten, 33570
- Suspendiert
- Moffitt Cancer Center at SouthShore
-
Tampa, Florida, Vereinigte Staaten, 33612
- Rekrutierung
- Moffitt Cancer Center - McKinley Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-679-0775
- E-Mail: ClinicalTrials@moffitt.org
-
Hauptermittler:
- Andrew J. Sinnamon
-
Tampa, Florida, Vereinigte Staaten, 33607
- Suspendiert
- Moffitt Cancer Center-International Plaza
-
Tampa, Florida, Vereinigte Staaten, 33612
- Suspendiert
- Moffitt Cancer Center
-
Wesley Chapel, Florida, Vereinigte Staaten, 33544
- Suspendiert
- Moffitt Cancer Center at Wesley Chapel
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- Suspendiert
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, Vereinigte Staaten, 30308
- Suspendiert
- Emory University Hospital Midtown
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Suspendiert
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Vereinigte Staaten, 30303
- Suspendiert
- Grady Health System
-
Johns Creek, Georgia, Vereinigte Staaten, 30097
- Suspendiert
- Emory Johns Creek Hospital
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Rekrutierung
- Northwestern University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-695-1301
- E-Mail: cancer@northwestern.edu
-
Hauptermittler:
- Akhil Chawla
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rekrutierung
- University of Illinois
-
Hauptermittler:
- Aslam Ejaz
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-355-3046
-
Geneva, Illinois, Vereinigte Staaten, 60134
- Suspendiert
- Northwestern Medicine Cancer Center Delnor
-
Oak Brook, Illinois, Vereinigte Staaten, 60523
- Suspendiert
- Northwestern Medicine Oak Brook
-
Orland Park, Illinois, Vereinigte Staaten, 60462
- Suspendiert
- Northwestern Medicine Orland Park
-
Warrenville, Illinois, Vereinigte Staaten, 60555
- Suspendiert
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Suspendiert
- Indiana University/Melvin and Bren Simon Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- Rekrutierung
- University of Kentucky/Markey Cancer Center
-
Hauptermittler:
- Michael J. Cavnar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 859-257-3379
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Suspendiert
- University Medical Center New Orleans
-
-
Maryland
-
Elkton, Maryland, Vereinigte Staaten, 21921
- Suspendiert
- Christiana Care - Union Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Suspendiert
- University of Michigan Rogel Cancer Center
-
Battle Creek, Michigan, Vereinigte Staaten, 49017
- Suspendiert
- Bronson Battle Creek
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Suspendiert
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Suspendiert
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Suspendiert
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Muskegon, Michigan, Vereinigte Staaten, 49444
- Suspendiert
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Vereinigte Staaten, 49120
- Suspendiert
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Vereinigte Staaten, 49444
- Suspendiert
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Vereinigte Staaten, 49677
- Suspendiert
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, Vereinigte Staaten, 49085
- Suspendiert
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Vereinigte Staaten, 49085
- Suspendiert
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Wyoming, Michigan, Vereinigte Staaten, 49519
- Suspendiert
- University of Michigan Health - West
-
-
Minnesota
-
Aitkin, Minnesota, Vereinigte Staaten, 56431
- Suspendiert
- Riverwood Healthcare Center
-
Baxter, Minnesota, Vereinigte Staaten, 56425
- Suspendiert
- Essentia Health - Baxter Clinic
-
Brainerd, Minnesota, Vereinigte Staaten, 56401
- Suspendiert
- Essentia Health Saint Joseph's Medical Center
-
Crosslake, Minnesota, Vereinigte Staaten, 56442
- Suspendiert
- Essentia Health - Saint Joseph's Crosslake Clinic
-
Deer River, Minnesota, Vereinigte Staaten, 56636
- Suspendiert
- Essentia Health - Deer River Clinic
-
Detroit Lakes, Minnesota, Vereinigte Staaten, 56501
- Suspendiert
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth, Minnesota, Vereinigte Staaten, 55805
- Suspendiert
- Essentia Health Saint Mary's Medical Center
-
Duluth, Minnesota, Vereinigte Staaten, 55805
- Suspendiert
- Miller-Dwan Hospital
-
Duluth, Minnesota, Vereinigte Staaten, 55805
- Suspendiert
- Essentia Health Cancer Center
-
Ely, Minnesota, Vereinigte Staaten, 55731
- Suspendiert
- Essentia Health - Ely Clinic
-
Fosston, Minnesota, Vereinigte Staaten, 56542
- Suspendiert
- Essentia Health - Fosston
-
Hibbing, Minnesota, Vereinigte Staaten, 55746
- Suspendiert
- Essentia Health Hibbing Clinic
-
International Falls, Minnesota, Vereinigte Staaten, 56649
- Suspendiert
- Essentia Health - International Falls Clinic
-
Moose Lake, Minnesota, Vereinigte Staaten, 55767
- Suspendiert
- Essentia Health - Moose Lake Clinic
-
Park Rapids, Minnesota, Vereinigte Staaten, 56470
- Suspendiert
- Essentia Health - Park Rapids
-
Pequot Lakes, Minnesota, Vereinigte Staaten, 56472
- Suspendiert
- Essentia Health - Saint Joseph's Pequot Lakes Clinic
-
Pine River, Minnesota, Vereinigte Staaten, 56474
- Suspendiert
- Essentia Health - Saint Joseph's Pine River Clinic
-
Sandstone, Minnesota, Vereinigte Staaten, 55072
- Suspendiert
- Essentia Health Sandstone
-
Staples, Minnesota, Vereinigte Staaten, 56479
- Suspendiert
- Essentia Health - Saint Joseph's Staples Clinic
-
Virginia, Minnesota, Vereinigte Staaten, 55792
- Suspendiert
- Essentia Health Virginia Clinic
-
-
Missouri
-
Farmington, Missouri, Vereinigte Staaten, 63640
- Rekrutierung
- Parkland Health Center - Farmington
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Sainte Genevieve, Missouri, Vereinigte Staaten, 63670
- Rekrutierung
- Sainte Genevieve County Memorial Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
St Louis, Missouri, Vereinigte Staaten, 63131
- Rekrutierung
- Missouri Baptist Medical Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Sullivan, Missouri, Vereinigte Staaten, 63080
- Rekrutierung
- Missouri Baptist Sullivan Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Sunset Hills, Missouri, Vereinigte Staaten, 63127
- Rekrutierung
- BJC Outpatient Center at Sunset Hills
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- Suspendiert
- University of Nebraska Medical Center
-
-
Nevada
-
Reno, Nevada, Vereinigte Staaten, 89502
- Suspendiert
- Renown Regional Medical Center
-
-
New Jersey
-
Livingston, New Jersey, Vereinigte Staaten, 07039
- Suspendiert
- Saint Barnabas Medical Center
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Suspendiert
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- Suspendiert
- University of New Mexico Cancer Center
-
-
New York
-
Rochester, New York, Vereinigte Staaten, 14642
- Suspendiert
- University of Rochester
-
Syracuse, New York, Vereinigte Staaten, 13210
- Suspendiert
- State University of New York Upstate Medical University
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28203
- Suspendiert
- Carolinas Medical Center/Levine Cancer Institute
-
Concord, North Carolina, Vereinigte Staaten, 28025
- Suspendiert
- Atrium Health Cabarrus/LCI-Concord
-
-
North Dakota
-
Fargo, North Dakota, Vereinigte Staaten, 58103
- Suspendiert
- Essentia Health Cancer Center-South University Clinic
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Suspendiert
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Suspendiert
- Sanford Broadway Medical Center
-
Jamestown, North Dakota, Vereinigte Staaten, 58401
- Suspendiert
- Essentia Health - Jamestown Clinic
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45219
- Suspendiert
- University of Cincinnati Cancer Center-UC Medical Center
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Suspendiert
- Ohio State University Comprehensive Cancer Center
-
West Chester, Ohio, Vereinigte Staaten, 45069
- Suspendiert
- University of Cincinnati Cancer Center-West Chester
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18104
- Rekrutierung
- Saint Luke's Cancer Center - Allentown
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-776-4714
-
Hauptermittler:
- Darius C. Desai
-
Bethlehem, Pennsylvania, Vereinigte Staaten, 18015
- Rekrutierung
- Saint Luke's University Hospital-Bethlehem Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 484-503-4151
-
Hauptermittler:
- Darius C. Desai
-
Chadds Ford, Pennsylvania, Vereinigte Staaten, 19317
- Suspendiert
- Christiana Care Health System-Concord Health Center
-
Easton, Pennsylvania, Vereinigte Staaten, 18045
- Rekrutierung
- Saint Luke's Hospital-Anderson Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-Mail: ctsucontact@westat.com
-
Hauptermittler:
- Darius C. Desai
-
Quakertown, Pennsylvania, Vereinigte Staaten, 18951
- Rekrutierung
- Saint Luke's Hospital - Upper Bucks Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-776-4714
-
Hauptermittler:
- Darius C. Desai
-
Stroudsburg, Pennsylvania, Vereinigte Staaten, 18360
- Rekrutierung
- Saint Luke's Hospital - Monroe Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-Mail: ctsucontact@westat.com
-
Hauptermittler:
- Darius C. Desai
-
Wilkes-Barre, Pennsylvania, Vereinigte Staaten, 18711
- Suspendiert
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57104
- Suspendiert
- Sanford Cancer Center Oncology Clinic
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5134
- Suspendiert
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37920
- Suspendiert
- University of Tennessee - Knoxville
-
Memphis, Tennessee, Vereinigte Staaten, 38120
- Suspendiert
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Vermont
-
Burlington, Vermont, Vereinigte Staaten, 05405
- Suspendiert
- University of Vermont and State Agricultural College
-
Burlington, Vermont, Vereinigte Staaten, 05401
- Suspendiert
- University of Vermont Medical Center
-
-
Virginia
-
Richmond, Virginia, Vereinigte Staaten, 23235
- Rekrutierung
- VCU Massey Cancer Center at Stony Point
-
Kontakt:
- Site Public Contact
- E-Mail: ctoclinops@vcu.edu
-
Hauptermittler:
- Leopoldo J. Fernandez
-
Richmond, Virginia, Vereinigte Staaten, 23298
- Rekrutierung
- VCU Massey Comprehensive Cancer Center
-
Hauptermittler:
- Leopoldo J. Fernandez
-
Kontakt:
- Site Public Contact
- Telefonnummer: 804-628-6430
- E-Mail: CTOclinops@vcu.edu
-
Roanoke, Virginia, Vereinigte Staaten, 24033
- Suspendiert
- Carilion Roanoke Memorial Hospital
-
Winchester, Virginia, Vereinigte Staaten, 22601
- Suspendiert
- Valley Health / Winchester Medical Center
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98195
- Suspendiert
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Vereinigte Staaten, 98109
- Suspendiert
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Ashland, Wisconsin, Vereinigte Staaten, 54806
- Suspendiert
- Northwest Wisconsin Cancer Center
-
Ashland, Wisconsin, Vereinigte Staaten, 54806
- Suspendiert
- Duluth Clinic Ashland
-
Hayward, Wisconsin, Vereinigte Staaten, 54843
- Suspendiert
- Essentia Health-Hayward Clinic
-
Hayward, Wisconsin, Vereinigte Staaten, 54843
- Suspendiert
- Tamarack Health Hayward Medical Center
-
Marshfield, Wisconsin, Vereinigte Staaten, 54449
- Rekrutierung
- Marshfield Medical Center-Marshfield
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Jessica A. Wernberg
-
Mukwonago, Wisconsin, Vereinigte Staaten, 53149
- Suspendiert
- ProHealth D N Greenwald Center
-
Oconomowoc, Wisconsin, Vereinigte Staaten, 53066
- Suspendiert
- ProHealth Oconomowoc Memorial Hospital
-
Spooner, Wisconsin, Vereinigte Staaten, 54801
- Suspendiert
- Essentia Health-Spooner Clinic
-
Superior, Wisconsin, Vereinigte Staaten, 54880
- Suspendiert
- Essentia Health Saint Mary's Hospital - Superior
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- Suspendiert
- ProHealth Waukesha Memorial Hospital
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- Suspendiert
- UW Cancer Center at ProHealth Care
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential
-
Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration/randomization date
-
Participants must not have a known history of a prior diagnosis of malabsorption syndrome
-
Participants must not have been treated with any somatostatin analogue within 180 days prior to registration/randomization
-
Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration/randomization
-
Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration/randomization
-
Participants must be ≥ 18 years old
-
Participants must have a complete documented medical history and physical exam within 28 days prior to registration/randomization
-
Participants must have a creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL/min using the following Cockcroft -Gault formula within 60 days prior to registration/randomization
-
Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include:
- Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed
- Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels
- Bromocriptine: Dose adjustments may be considered to account for absorption changes
- Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary
- CYP3A4-metabolized medications: Dose adjustments may be considered to avoid increased exposure
-
In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy
- NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible
-
In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation
-
Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either aspartate aminotransferase [AST] > 190 U/L or alanine aminotransferase [ALT] > 320 U/L) within 60 days prior to registration/randomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable
-
Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped)
-
Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
-
Participants must be offered the opportunity to participate in specimen banking
-
Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study
-
NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
-
For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Arm I (lanreotide, distal pancreatectomy)
Patients receive lanreotide SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. |
Ancillary studies Undergo blood sample and pancreas fluid collection
Andere Namen:
Undergo distal pancreatectomy Given SC
Andere Namen:
|
|
Placebo-Komparator: Arm II (saline placebo, distal pancreatectomy)
Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. |
Ancillary studies Undergo blood sample and pancreas fluid collection
Andere Namen:
Undergo distal pancreatectomy Given SC
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of postoperative pancreatic fistula (POPF)
Zeitfenster: Up to 60 days after distal pancreatectomy
|
POPF will be assessed using the 2016 International Study Group for Pancreas Surgery (ISGPS). Incidence rates of POPF in each treatment arm will be described, and treatment arm differences assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of biochemical leak (BL)
Zeitfenster: Up to 60 days after distal pancreatectomy
|
BL will be defined by the ISGPS as a peritoneal drain amylase greater than three times the upper limit of the institutional normal serum amylase without an effect on clinical management or duration of hospital stay. BL will only be measured in those who had a peritoneal drain placed. Treatment arm differences will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Number of post-operation hospital days
Zeitfenster: From the time of surgery up to 60 days after distal pancreatectomy
|
Mean hospital length of stay will be compared according to treatment arm via linear regression model with adjustment for stratification factor. |
From the time of surgery up to 60 days after distal pancreatectomy
|
|
Change in overall quality of life (QOL)
Zeitfenster: At baseline and at 14 and 60 days after surgery
|
Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Core 30 (C30). Treatment arm differences in EORTC QLQ-C30 changes will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and at 14 and 60 days after surgery
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Changes in pancreatic specific QOL
Zeitfenster: At baseline and up to 60 days after distal pancreatectomy
|
Will be assessed using EORTC QLQ- Pancreatic Cancer 26. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and up to 60 days after distal pancreatectomy
|
|
Change in health-related QOL
Zeitfenster: At baseline and up to 60 days after distal pancreatectomy
|
Will be assessed using the European Quality of Life Five Dimension Five Level scale. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and up to 60 days after distal pancreatectomy
|
|
Delayed gastric emptying (DGE)
Zeitfenster: Up to 60 days after distal pancreatectomy
|
DGE will be defined by the ISGPS as reinsertion or persistence of a nasogastric tube after postoperative day (POD) 3 or inability to tolerate solid oral intake by POD 7. Treatment arm differences in the proportion of participants with DGE will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Incidence of grades B/C post-pancreatectomy hemorrhage (PPH)
Zeitfenster: Up to 60 days after distal pancreatectomy
|
PPH will be defined by the ISGPS as postoperative intra- or extra-luminal hemorrhage requiring transfusion of fluid or blood, intensive care unit transfer, therapeutic endoscopy, endovascular embolization, or reoperation. Treatment arm differences in the proportion of participants with PPH will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Time to initiation of adjuvant chemotherapy
Zeitfenster: From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
|
Distributions of time from surgery to initiation of adjuvant chemotherapy, among participants with planned adjuvant chemotherapy, in each arm will be estimated via cumulative incidence and compared using the stratified log-rank test. |
From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
|
|
Incidence of nausea and vomiting
Zeitfenster: Up to 60 days after distal pancreatectomy
|
Proportions of participants with any nausea/vomiting will be compared between treatment arms via Fisher's exact test. |
Up to 60 days after distal pancreatectomy
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Jonathan G Sham, SWOG Cancer Research Network
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des endokrinen Systems
- Neubildungen nach Standort
- Neubildungen
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Neoplasmen der endokrinen Drüse
- Erkrankungen der Bauchspeicheldrüse
- Neoplasmen der Bauchspeicheldrüse
- Pharmazeutische Präparate
- Untersuchungstechniken
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Anorganische Chemikalien
- Chlorverbindungen
- Kristalloidlösungen
- Isotonische Lösungen
- Lösungen
- Natriumverbindungen
- Chloride
- Salzsäure
- Salzlösung
- Handhabung von Proben
- Natriumchlorid
- Lanreotid
Andere Studien-ID-Nummern
- S2408
- UG1CA189974 (US NIH Stipendium/Vertrag)
- NCI-2024-08361 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- SWOG-S2408 (Andere Kennung: DCP)
- S2408 (Andere Kennung: SWOG)
- S2408 (Andere Kennung: CTEP)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .